Patrick Alexander Ott
Broad Institute · 636 works · 41,679 citations · h-index 82
Top works
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- An immunogenic personal neoantigen vaccine for patients with melanoma
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
- PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients